GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
GAITHERSBURG, Md., December 05, 2008 /PRNewswire-FirstCall/ -- GenVec, Inc. announced today that the company will present on GenVec's malaria vaccine program at the American Society of Tropical Medicine and Hygiene (ASTMH) 57th Annual Meeting, which will take place in New Orleans, LA on December 7-11, 2008. Two presentations, highlighting research conducted in this program, will be given by GenVec scientists. Additional presentations, to be given by GenVec collaborators, will provide updates on malaria vaccine development, ranging from preclinical research through ongoing clinical studies using GenVec's core adenovector technology.
Joseph L. Bruder, Ph.D., GenVec's Director of Vector and Vaccine Programs, will give two research presentations: "Advanced generation adeno-based vectors for malaria vaccine development" and "Development of a multi-antigen multi-stage adenovector-based malaria vaccine that induces robust T-cell and antibody responses." These presentations will be available on GenVec's website on December 11, 2008. To view these presentations, visit www.genvec.com, click on "Investor Relations" and then "Webcasts and Data."
"Research presented at the ASTMH Annual meeting highlights the potential of GenVec's vaccine programs," stated Dr. Rick King, GenVec's Senior Vice President of Research. "We are excited about the prospective use of our technology in the prevention of malaria."
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
CONTACT: Douglas J. Swirsky, Chief Financial Officer, GenVec, Inc.,+1-240-632-5510, firstname.lastname@example.org
Web site: http://www.genvec.com/
Ticker Symbol: (NASDAQ-NMS:GNVC),(NASDAQ-NMS:GNVC)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2008